Avodart is a medication with the active ingredient dutasteride. It is also known by its generic name, dutasteride, and sometimes sold under other brand names. Avodart is used to treat benign prostatic hyperplasia (BPH), also called an enlarged prostate, in men.
Avodart pricing spectrum extends from £0.54 to £0.96 for each pills. The key influencers are pack magnitude and the grade of active substances (30 or 360 mg).
Avodart, also known by its generic name dutasteride, is primarily used for the treatment of benign prostatic hyperplasia (BPH). It falls under the therapeutic class of 5-alpha-reductase inhibitors.
The medication is available in the form of soft gelatin capsules. Each capsule contains 0.5 mg of the active ingredient, dutasteride.
Avodart is primarily prescribed for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It may also be prescribed in combination with other medications like tamsulosin to alleviate symptoms associated with BPH.
The recommended dosage of Avodart is one 0.5 mg capsule taken orally once daily. The capsule should be swallowed whole and not chewed, crushed, or opened, as the medication is absorbed through the skin and may lead to unwanted side effects.
Dutasteride is rapidly absorbed with peak plasma concentrations reached 2–3 hours after oral intake. It has a large volume of distribution and is extensively metabolized by the liver. The elimination half-life of dutasteride is approximately 5 weeks in healthy volunteers.
Common side effects may include impotence, decreased libido, breast tenderness, or enlargement of the breast tissue. Serious side effects may involve severe allergic reactions, swelling, and difficulty breathing. Persistent or worsening symptoms should be reported to a healthcare professional immediately.
Avodart may interact with other medications metabolized by the liver enzymes, primarily CYP3A4 inhibitors. Such interactions can alter the effectiveness of Avodart or increase the risk of adverse effects. Noteworthy medications include ketoconazole, ritonavir, and verapamil. Co-administration with these drugs should be supervised by a healthcare provider.
Avodart is contraindicated in patients with known hypersensitivity to dutasteride or any component of the formulation. It is also contraindicated in women, particularly during pregnancy and breastfeeding, due to the potential for birth defects and other adverse effects on fetal development.
The use of Avodart in pediatric populations is not recommended. Caution and dosage adjustments may be necessary in elderly patients or those with hepatic impairment. Additionally, men considering fathering a child should be aware of the potential risk to the fetus and discuss their options with a healthcare provider.
Regular monitoring should include prostate-specific antigen (PSA) levels and liver function tests. An initial decrease in PSA levels may be expected, but any subsequent increases should be evaluated for potential indicators of prostate cancer.
Patients should be informed about the importance of taking Avodart consistently and at the same time each day. Advise them not to stop taking the medication without consulting their healthcare provider. Furthermore, patients should be made aware of the potential side effects and be instructed to report any unusual symptoms promptly.
Store Avodart capsules at controlled room temperature, between 20-25°C (68-77°F). Keep the medication in its original packaging to protect it from moisture. Handle capsules with dry hands and avoid contact with broken or damaged capsules, as the active ingredient can be absorbed through the skin.
If a dose is missed, the patient should take it as soon as they remember. However, if it is close to the time for the next scheduled dose, they should skip the missed dose and resume the regular dosing schedule. Doubling up on doses to make up for a missed one is not recommended.
Patients should expect symptom improvement within 6 months of starting treatment. Regular follow-ups with the healthcare provider are crucial for assessing the effectiveness of the medication and making any necessary adjustments. Symptom diaries or logs can be beneficial for tracking progress.
Avodart can lower the levels of prostate-specific antigen (PSA) in the blood by approximately 50%. This factor needs to be considered when interpreting PSA test results to avoid misdiagnosing or overlooking prostate cancer. Physicians should establish a new baseline PSA value for patients taking Avodart.
Long-term use of Avodart has not been associated with significant health issues, but ongoing studies continue to monitor its safety profile. Any new or unexplained health changes in patients taking the medication long-term should be reported and evaluated by a healthcare provider.
Avodart capsules are an opaque, yellow, oblong shape printed with “GX CE2” in red ink on one side. Each capsule contains a combination of gelatin, glycerin, titanium dioxide, and ferric oxide yellow in its composition.
Avodart is approved by regulatory agencies such as the FDA for the treatment of BPH. It is a prescription-only medication and should be dispensed by a licensed pharmacy. Users should only procure Avodart from verified, legal sources.
Avodart belongs to the pharmacologic class of 5-alpha-reductase inhibitors. This category of drugs functions by reducing the production of dihydrotestosterone (DHT), a hormone that contributes to prostate growth.
Given the potential risks and side effects, healthcare providers should ensure patients provide informed consent before starting Avodart. Patients should be fully aware of all potential outcomes and agree to regular monitoring as part of the treatment plan.